Post-earnings recap
Reported
Mon, Aug 6, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Krystal Biotech's earnings report showed a loss per share of $0.22, but the stock still rose by 1.52%. Investors may be optimistic about the company's ongoing clinical trials and product development, despite the lack of revenue figures and guidance. The stock's positive reaction suggests that the market is willing to overlook the EPS miss for now.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.22 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management emphasized their commitment to advancing their pipeline. They acknowledged the challenges but did not provide specific forward-looking guidance.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The focus remains on ongoing clinical trials and product development.